Loading stock data…
Belite Bio, Inc (BLTE)
$192.85-0.76 (-0.39%)
Market ClosedLast close Sep 8
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Belite Bio, Inc in the Healthcare sector is trading at $192.85 with a market capitalization of $7.8B. Wall Street consensus targets $223.89 (9 analysts), implying a +16.1% move over the next 12 months. The stock is currently near its 52-week high of $200.00, remaining 22.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +16.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$32.68M↓ | -$28.08M↓ | -$23.02M↓ | -$17.60M↓ | -$15.52M |
| Net Income | -$26.94M↓ | -$25.32M↓ | -$21.69M↓ | -$16.32M↓ | -$14.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.77B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.18%
Volume
Today's trading volume
571,456
Recent News
UiPath downgraded, Shell upgraded: Wall Street's top analyst calls
UiPath downgraded, Shell upgraded: Wall Street's top analyst calls
Here Are Friday’s Top Wall Street Analyst Research Calls: Ambarella, Cal-Maine Foods, Lennar, Ormat Technologies, Paychex, PulteGroup, Shell plc, TotalEnergies, W.P. Carey, and More
Wall Street wrapped a turbulent week with a wave of upgrades and downgrades hitting energy giants, homebuilders, and tech names just ahead of the Labor Day weekend. Find out which stocks analysts are rushing to buy and which ones just lost their support.
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date. At the company’s 2026 Commercial Day, Chairman and CEO
Belite Bio (BLTE) Could Be 21% Undervalued On FDA Priority Review News
Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that accompanies the company’s latest quarterly earnings report. See our latest analysis for Belite Bio. Belite Bio’s share price has been volatile around these updates, with a one day share price return down 7.07% but a 30 day share price return of 11.25% and a one year total shareholder return of 149.56%. This suggests momentum has been strong over a...
Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run
Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to a less straightforward picture of how much is already priced in. Belite Bio has returned 431.2% over three years, which sets a high bar for any further upside to be justified by the fundamentals. Regulatory progress for tinlarebant, including the FDA Priority Review for Stargardt Disease Type 1, can support expectations for future cash...